Quick Takeaways
- Trails Edge Capital Partners, LP filed SCHEDULE 13G for Sensei Biotherapeutics, Inc. Common Shares, no par value per share (SNSE).
- Disclosed ownership: 9.9%.
- Date of event: 18 Feb 2026.
Quoteable Key Fact
"Trails Edge Capital Partners, LP disclosed 9.9% ownership in Sensei Biotherapeutics, Inc. Common Shares, no par value per share (SNSE) on 18 Feb 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Trails Edge Capital Partners, LP | 9.9% | 126,010 | 126,010 | 0 | /s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai | Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC | |
| Trails Edge Biotechnology Master Fund, LP | 9.9% | 126,010 | 126,010 | 0 | /s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai | Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC | |
| Ortav Yehudai | 9.9% | 126,010 | 126,010 | 0 | /s/ Ortav Yehudai | Ortav Yehudai / Individual |